Results 1 to 10 of about 346,833 (254)
Global Advances in Health and Medicine, 2013 The management of multiple sclerosis (MS) is changing at a rapid rate, with the emergence of a host of new therapeutic interventions in various stages of development. Despite the enthusiasm with which the pharmaceutical industry is hailing these interventions, there remains a need for people involved in the management of MS to be circumspect regarding ...
openaire +4 more sources
Seminars in Neurology, 2007 Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that commonly leads to inflammatory and atrophic brain pathology, often causing cognitive impairment. MS-associated cognitive impairment was first described over a century ago.
Ralph H B, Benedict, Julie H, Bobholz
openaire +3 more sources
Vaccines, 2023 Vaccines against the SARS-CoV-2 virus were authorized for use by the Food and Drug Administration (FDA) in the United States and have proven effective for the prevention of morbidity and death from COVID-19.
Luke B. Elias +5 more
doaj +1 more source
Nature Communications, 2019 An amendment to this paper has been published and can be accessed via a link at the top of the paper.
International Multiple Sclerosis Genetics Consortium
doaj +1 more source
Neurology and Therapy, 2023 The emergence of high-efficacy therapies for multiple sclerosis (MS), which target inflammation more effectively than traditional disease-modifying therapies, has led to a shift in MS management towards achieving the outcome assessment known as no ...
Scott D. Newsome +4 more
doaj +1 more source
Family Perspectives on Clinical Research for Pediatric Multiple Sclerosis: Enhancing Equity
Journal of Patient Experience, 2021 Pediatric new drug trials are federally mandated, but family perspectives in multiple sclerosis (MS) research are limited. Due to MS chronicity and long-term medical system involvement, we obtained family views on research priorities and optimized ...
Leslie A Mandel PhD, MA, MS +7 more
doaj +1 more source
Frontiers in Neurology, 2023 BackgroundAlemtuzumab (ALZ) is a humanized monoclonal antibody approved for the treatment of patients with highly active relapsing-remitting multiple sclerosis (RRMS) administered in two annual courses.
Sara Eichau +7 more
doaj +1 more source
European Journal of Medical Research, 2023 Introduction Balance disorders are common in people with Multiple Sclerosis (PwMS) and, together with other impairments and disabilities, often prevent PwMS from performing their daily living activities.
Jessica Podda +9 more
doaj +1 more source
Frontiers in Neurology, 2021 Background: Although cognition in multiple sclerosis (MS) is assessed by means of several neuropsychological tests, only a few tools exist to investigate patients' perspectives on cognitive functioning.Objective: To develop a new questionnaire aimed at ...
Alice Riccardi +12 more
doaj +1 more source
Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis
Biomolecular Concepts, 2017 Cytokines are implicated in the immunopathogenesis of multiple sclerosis (MS). Interleukin (IL)-33, one of the recently discovered members of the IL-1 superfamily, is a dual functional cytokine involved in various autoimmune disorders.
Alsahebfosoul Fereshteh +6 more
doaj +1 more source